Targeted Oncology

Considering the Evolution of ARPI Combination Therapy in mHSPC

Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...
Healio

Tumor board aims to treat cancer pain with same urgency as the malignancy

Tumor boards are an invaluable tool to share knowledge and ensure optimal treatment for people with cancer.The conversations ...
CURE

FDA Approves Revuforj for R/R NPM1-Mutant AML

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...
Targeted Oncology

Poll Responses Show Preference Among Expanding Relapsed CLL Therapies

To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A ...